2000 Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines

Journal of Clinical Oncology

Volumn 18, Issue 20, 2000, Pages 3558-3585

  Ozer, H ^a   Armitage, J O ^a   Bennett, C L ^a   Crawford, J ^a   Demetri, G D ^a   Pizzo, P A ^a   Schiffer, C A ^a   Smith, T J ^a   Somlo, G ^a   Wade, J C ^a   Wade III, J L ^a   Winn, R J ^a   Wozniak, A J ^a   Somerfield, M R ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA TOPOISOMERASE INHIBITOR; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; NAVELBINE; PACLITAXEL; TAXANE DERIVATIVE;

ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUING EDUCATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; EVIDENCE BASED MEDICINE; FEBRILE NEUTROPENIA; GERM CELL TUMOR; HUMAN; INFECTION; LEUKOPENIA; MEDICAL EDUCATION; MEDICAL INFORMATION; NEUTROPENIA; NONHODGKIN LYMPHOMA; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034667860     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2000.18.20.3558     Document Type: Article

References (165)

1. A comparative study of two different doses of cytarabine for acute myeloid leukemia: A phase III trial of Cancer and Leukemia Group B
2. Treatment of epidemic Kaposi's sarcoma with etoposide or a combination of doxorubicin, bleomycin, and vinblastine
3. Liposomal-entrapped doxorubicin: An active agent in AIDS-related Kaposi's sarcoma
4. Clinical and virologic effects of recombinant human granulocyte-macrophage colony-stimulating factor in patients receiving chemotherapy for human immuno-deficiency virus-associated non-Hodgkin's lymphoma: Results of a randomized trial
5. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection: National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group
6. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative study
7. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
8. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: A phase II trial
9. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma
10. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: Results from the National Surgical Adjuvant Breast and Bowel Project B-15
11. Multicenter randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer
12. Phase II and pharmacologic study of docetaxel as initial chemotherapy for metastatic breast cancer
13. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study
14. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer
15. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
16. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
17. Randomized study of cisplatin dose-intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol
18. Primary salvage treatment of recurrent germ cell tumors: Experience at Indiana University
19. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study
20. Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: A phase II study
21. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer (r-medHuG-CSF)
22. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
23. Topotecan (T) versus (vs) cyclophosphamide (C), doxorubicin (A) and vincristine (V) for the treatment (tx) of patients (pts) with recurrent small cell lung cancer (SCLC): A phase III study
24. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study
25. Natale R.B: Preliminary results of a phase I/II clinical trial of paclitaxel and carboplatin in non-small cell lung cancer
26. Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: A phase II study
27. Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD
28. Comparison of standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma
29. Combination chemotherapy, glucocorticoids, and interferon alfa in the treatment of multiple myeloma: A Southwest Oncology Group study
30. Effective treatment of advanced multiple myeloma refractory to alkylating agents
31. Comparison of combination therapy with paclitaxel and cisplatin versus cyclophosphamide and cisplatin in patients with suboptimal stage III and stage IV ovarian cancer: A Gynecologic Oncology Group study
32. Carboplatin and paclitaxel in ovarian carcinoma: A phase I study of the Gynecologic Oncology Group
33. Topotecan and the treatment of recurrent ovarian cancer: Is there a role for granulocyte colony-stimulating factor?
34. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcoma
35. Decision analysis of hematopoietic growth factor use in patients receiving cancer chemotherapy
36. An economic model to assess the savings from a clinical application of haematopoietic growth factors
37. Low-dose versus standard-dose lenograstim prophylaxis after chemotherapy: A randomized, crossover comparison
38. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer
39. Anonymous: Drugs of choice for chemotherapy
40. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia
41. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia
42. Management of fever in patients with cancer and treatment-induced neutropenia
43. The medical course of cancer patients with fever and neutropenia
44. Risk assessment in cancer patients with fever and neutropenia: A prospective, two-center validation of a prediction rule
45. Outpatient treatment of febrile episodes in low-risk neutropenic patients with cancer
46. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double-blind placebo-controlled study in children
47. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
48. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation
49. Selective decontamination of the digestive tract and its role in antimicrobial prophylaxis
50. Clinical impact of chemotherapy dose escalation in patients with hematological malignancies and solid tumors
51. Design and interpretation of clinicals trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy
52. Hematopoietic growth factors and treatment of testicular cancer: Biological interactions, routine use and dose-intensive chemotherapy
53. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell
54. 1997 Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever
55. Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
56. Randomized trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement
57. Randomized trial of high-dose chemotherapy for high-risk primary breast carcinoma
58. Conventionaldose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer: Philadelphia Bone Marrow Transplantation Group
59. A prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): Preliminary results of CALGB 9082/SWOG 9114/NCIC MA-13
60. Wade J.C: Management of infection in patients with acute leukemia
61. Use of hematopoietic colony-stimulating factors: The American Society of Clinical Oncology survey
62. NCCN practice guidelines for fever and neutropenia: National Comprehensive Cancer Network
63. Home antibiotic therapy for low-risk cancer patients with fever and neutropenia: A pilot study of 30 patients based on a validated prediction rule
64. Optimal timing of G-CSF administration in patients receiving chemotherapy for non-small cell lung cancer (NSCLC)
65. Intervention treatment of established neutropenia with human recombinant granulocyte-macrophage colony-simulating factor (rhGM-CSF) in patients undergoing cancer chemotherapy
66. Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia
67. Filgrastim in patient with chemotherapy-induced febrile neutropenia: A double-blind, placebo-controlled trial
68. Granulocyte colony-stimulating factor in established febrile neutropenia: A randomized study of pediatric patients
69. Randomized placebo-controlled trial of granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related febrile neutropenia
70. Randomized comparison between antibiotics alone and antibiotics plus granulocyte-macrophage colony-simulating factor (Escherichia coli-derived) in cancer patients with fever and neutropenia
71. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors
72. Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: Results of a randomized phase III trial
73. Recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of febrile neutropenia: A double-blind placebo-controlled study in children
74. Efficacy and tolerability of recombinant human granulocyte-macrophage colony-stimulating factor in patients with chemotherapy-related leukopenia and fever
75. American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based, clinical practice guidelines
76. Filgrastim in the treatment of high-risk febrile neutropenia: Results of a multicenter randomized phase III trial
77. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: A prospective randomized study of 300 patients
78. A phase II trial of 200% ProMACE-CytaBOM in patients with previously untreated aggressive lymphomas: Analysis of response, toxicity, and dose intensity
79. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: A dose-finding pilot study
80. Dose-escalation of CHOP in non-Hodgkin's lymphoma
81. Phase I and subsequent phase II study of filgrastim (r-met-HuG-CSF) and dose intensified cyclophosphamide plus epirubicin in patients with non-Hodgkin's lymphoma and advanced solid tumors
82. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma
83. GM-CSF instead of autologous bone-marrow transplantation after the BEAM regimen
84. The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer
85. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: Results of a British Medical Research Council multicenter randomized trial
86. Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: A randomized comparison
87. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients
88. High-dose chemotherapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor mobilized peripheral blood stem cells
89. Results of a randomized controlled multicenter study of recombinant human granulocyte colony stimulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation
90. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: A prospective, randomized trial
91. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation
92. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts
93. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: Safety, kinetics of mobilization, and composition of the graft
94. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor)
95. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor
96. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors
97. Role of tumor cells contaminating the graft in breast cancer recurrence after high-dose chemotherapy
98. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer
99. Hematopoietic recovery after allogeneic blood stem-cell transplantation compared with bone marrow transplantation in patients with hematologic malignancies
100. Allogeneic bone marrow transplantation vs filgrastim-mobilized peripheral blood progenitor cell transplantation in patients with early leukemia: First results of a randomized multicentre trial of the European Group for Blood and Marrow Transplantation
101. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease
102. A prospective randomised trial of peripheral blood stem cells (PBSC) or marrow (BM) for patients undergoing allogeneic transplantation for hematologic malignancies
103. Delayed G-CSF after autologous progenitor cell transplantation: A prospective randomized trial
104. Early vs delayed addition of G-CSF following autologous peripheral blood stem cell transplantation
105. G-CSF after peripheral blood stem cell transplantation in lymphoma patients significantly accelerated neutrophil recovery and shortened time in hospital: Results of a randomized BNLI trial
106. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation
107. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation
108. A randomized, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for hematopoietic stem cell mobilization in patients with severe rheumatoid arthritis
109. Pluripotent and lineage-committed CD34+ subsets in leukapheresis products mobilized by G-CSF, GM-CSF vs. a combination of both
110. A combination of low-dose cyclophosphamide and colony-stimulating factors is more cost-effective than granulocyte-colony-stimulating factors alone in mobilizing peripheral blood stem and progenitor cells
111. CD34+ cells mobilized by cyclophosphamide and granulocyte colony stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF
112. Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: An assessment of risk factors
113. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: A randomized comparison of GM-CSF vs. G-CSF
114. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myeloid leukemia: AML Cooperative Study Group
115. A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490)
116. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia: Cancer and Leukemia Group B
117. A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia
118. A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukemia: A Southwest Oncology Group study (9031)
119. Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia
120. Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: Final report of AML-111, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Group
121. Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: A randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group
122. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients
123. Cost analyses of adjunct colony stimulating factors for acute leukemia: Can they improve clinical decision making
124. Economic analyses of phase III cooperative cancer group clinical trials: Are they feasible?
125. Economic analysis of granulocyte colony-stimulating factor as adjunct therapy for older patients with acute myelogenous leukemia (AML): Estimates from a Southwest Oncology Group clinical trial
126. Cost impact of filgrastim as an adjunct to chemotherapy for patients with acute myeloid leukemia
127. Effect of recombinant GM-CSF on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells
128. A phase III trial with or without GM-CSF administered before and during high dose cytarabine in patients with relapsed or refractory acute myelogenous leukemia: CALGB 9021
129. A double-blind controlled study of granulocyte-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia: Kohseisho Leukemia Study Group
130. G-CSF after intensive consolidation chemotherapy in acute myeloid leukemia: Results of a randomized trial of the Groupe Ouest-Est Leucemies Aigues Myeloblastiques
131. Effects of human granulocyte-macrophage colony-stimulating factor in patients with myelodysplastic syndromes
132. Maintenance treatment of patients with myelodysplastic syndromes using recombinant human granulocyte colony stimulating factor
133. Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS)
134. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia
135. Human granulocyte colony-stimulating factor after induction chemotherapy in children with acute lymphoblastic leukemia
136. Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia: A randomized Phase III Trial
137. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia: Berlin-Frankfurt-Munster Study Group
138. Granulocyte colony-stimulating factor as an adjunct to induction chemotherapy for adult acute lymphoblastic leukemia: A randomized phase-III study
139. Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL)
140. Effects of r-metHuG-CSF in an intensive treatment for T-cell leukemia and advanced stage lymphoblastic lymphoma of childhood: A Pediatric Oncology Group pilot study
141. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia
142. Intensive chemotherapy with mitoxantrone and high dose cytosine arabinoside followed by granulocyte-macrophage colony-stimulating factor in the treatment of patients with acute lymphocytic leukemia
143. Platinum-radiation interactions
144. Cisplatin potentiation or radiotherapy
145. Nonsurgical management of esophageal cancer: Report of a study of combined radiotherapy and chemotherapy
146. Radical radiation therapy with 5-fluorouracil infusion and mitomycin C for esophageal squamous carcinoma
147. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus
148. Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin
149. Treatment of locally advanced non-small cell lung cancer
150. Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium
151. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group
152. Growth factor practice patterns among pediatric oncologists: Results of a 1998 Pediatric Oncology Group survey - Economic Evaluation Working Group the Pediatric Oncology Group
153. Dose-ranging study of recombinant human granulocyte-macrophage colony-stimulating factor in small-cell lung carcinoma
154. Randomized trial showing equivalent efficacy of filgrastim 5 mg/kg/d and 10 mg/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomas
155. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers
156. Mobilization and harvesting of peripheral blood stem cells: Randomized evaluations of different doses of filgrastim
157. Priming with G-CSF 10 mg/kg is more effective than 5 mg/kg in patients receiving high-dose chemotherapy followed by peripheral stem cell rescue
158. Filgrastim priming of PBSC and hematopoietic reconstitution following high-dose chemotherapy for breast cancer: Effect of dose on PBSC yield and engraftment
159. Effect of CD34+ selection and various schedules of stem cell reinfusion and granulocyte colony stimulating factor priming on hematopoietic recovery after high-dose chemotherapy for breast cancer
160. Pharmacokinetics of recombinant human granulocyte-macrophage colony-stimulating factor in children after intravenous and subcutaneous administration
161. Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: Increased efficacy and reduced toxicity when given subcutaneously
162. Pharmacology of filgrastim (r-metHuG-CSF)
163. Update of recommendations for the use of hematopoietic colony-stimulating factors: Evidence-based clinical practice guidelines
164. A comparison of the efficacy of sargramostim (yeast-derived RhuGM-CSF) and filgrastim (bacteria-derived RhuG-CSF) in the therapeutic setting of chemotherapy-induced myelosuppression
165. Randomized trial of filgrastim, sargramostim, or sequential sargramostim and filgrastim after myelosuppressive chemotherapy for the harvesting of peripheral-blood stem cells